Price Action Alert: What’s Aduro BioTech Inc Upside After Today’s Big Increase?

Price Action Alert: What's Aduro BioTech Inc Upside After Today's Big Increase?

The stock of Aduro BioTech Inc (NASDAQ:ADRO) is a huge mover today! The stock increased 2.98% or $0.37 during the last trading session, hitting $12.8. About 517,007 shares traded hands or 14.95% up from the average. Aduro BioTech Inc (NASDAQ:ADRO) has declined 14.63% since February 29, 2016 and is downtrending. It has underperformed by 26.85% the S&P500.
The move comes after 5 months positive chart setup for the $855.70 million company. It was reported on Oct, 4 by Barchart.com. We have $18.94 PT which if reached, will make NASDAQ:ADRO worth $410.74M more.

Analysts await Aduro BioTech Inc (NASDAQ:ADRO) to report earnings on November, 28. They expect $-0.49 EPS, down 5,000.00% or $0.50 from last year’s $0.01 per share. After $0.03 actual EPS reported by Aduro BioTech Inc for the previous quarter, Wall Street now forecasts -1,733.33% negative EPS growth.

Aduro BioTech Inc (NASDAQ:ADRO) Ratings Coverage

Out of 6 analysts covering Aduro Biotech (NASDAQ:ADRO), 3 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 50% are positive. Aduro Biotech has been the topic of 9 analyst reports since August 19, 2015 according to StockzIntelligence Inc. The stock of Aduro BioTech Inc (NASDAQ:ADRO) earned “Buy” rating by Roth Capital on Tuesday, November 24. Zacks upgraded Aduro BioTech Inc (NASDAQ:ADRO) on Thursday, September 3 to “Hold” rating. The stock of Aduro BioTech Inc (NASDAQ:ADRO) earned “Outperform” rating by Oppenheimer on Tuesday, October 20. The firm has “Outperform” rating by FBR Capital given on Tuesday, May 17. The rating was downgraded by Oppenheimer on Tuesday, December 1 to “Perform”. The company was downgraded on Tuesday, March 15 by Bank of America. Leerink Swann initiated the stock with “” rating in Wednesday, August 19 report. The rating was maintained by TH Capital with “Buy” on Tuesday, November 24. The firm has “Buy” rating given on Thursday, August 27 by Roth Capital.

According to Zacks Investment Research, “Aduro Biotech, Inc. is an immunotherapy company. The Company develops technology and vaccines for the treatment of cancer and mesothelin-expressing tumors. Its product pipeline includes CRS-207, ADU-623, ADU-214, ADU-741, CDN and STINGVAX which are in different clinical trial. Aduro Biotech, Inc. is based in BERKELEY, United States.”

More notable recent Aduro BioTech Inc (NASDAQ:ADRO) news were published by: Marketwatch.com which released: “Aduro Biotech gains on BioNovion acquisition” on September 24, 2015, also Prnewswire.com with their article: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” published on May 16, 2016, Fool.com published: “Why Aduro Biotech Is Crashing Today” on November 24, 2015. More interesting news about Aduro BioTech Inc (NASDAQ:ADRO) were released by: Globenewswire.com and their article: “Aduro Biotech Announces New Corporate Offices and Laboratory Space” published on September 01, 2016 as well as 247Wallst.com‘s news article titled: “Is This the Beginning of the End of Aduro BioTech?” with publication date: May 16, 2016.

ADRO Company Profile

Aduro Biotech, Inc., incorporated on May 5, 2011, is a clinical-stage immunotherapy company. The Firm is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Firm has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies. The Company’s LADD technology platform is engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, LADD technology platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. The Company’s STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a tumor-specific immune response. The Company’s B-select monoclonal antibody platform includes various immune modulating assets in research and preclinical development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment